caa a22 4500 606239723 CHVBK 20210128101304.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s00508-014-0605-6 doi (NATIONALLICENCE)springer-10.1007/s00508-014-0605-6 Novel agents have a significant impact on survival of patients with multiple myeloma [Elektronische Daten] [Wolfgang Lamm, Sandra Eder, Marija Bojic, Christoph Zielinski, Johannes Drach] Neue Substanzen führen zu einer signifikanten Verlängerung des Gesamtüberlebens bei Patienten mit Multiplem Myelom Summary: Background: In addition to conventional chemotherapeutic regimens and autologous transplantation, novel agents are now part of the treatment armamentarium against multiple myeloma (MM). To evaluate the presumed benefit of novel agents, we performed an analysis of patients with MM at our institution before and after the availability of novel agents. Design and methods: In all, 200 consecutive patients with newly diagnosed MM (male=119; female=81; median age: 61.5 years) treated at our institution between June 1993 and December 2008 were included in this retrospective analysis. Patient cohorts were defined according to date of diagnosis (before and after 01-Jan-2000, respectively), treatment received (chemotherapy only vs. therapy including novel agents), risk profile (International Staging System (ISS)-stage), and cytogenetic features. Primary focus of the analysis was overall survival (OS). Results: Median OS for MM patients who received conventional chemotherapy was 45.2 months and for patients who received novel agents 74.6 months (P<0.01). OS for those patients who relapsed after autotransplantation before 2000 was 35.2 months, but 72.7 months (P<0.01) for those patients with a later relapse. Prolongation of survival for patients receiving novel agents was most evident for patients with ISS stage III (median OS 68.4 vs. 11.2 months for patients with chemotherapy only; P<0.01). MM patients with an intermediate risk had a longer median OS when receiving novel agents (47.2 vs. 32.8 months). Conclusion: Treatment with novel agents in MM resulted in a significant prolongation of OS. Benefit of therapy with novel agents was particularly evident for transplant-eligible patients and MM patients with unfavorable prognosis. Springer-Verlag Wien, 2014 Bortezomib nationallicence Conventional chemotherapy nationallicence Lenalidomide nationallicence Multiple myeloma nationallicence Thalidomide nationallicence Konventionelle Chemotherapie nationallicence Lenalidomid nationallicence Multiples Myelom nationallicence Thalidomid nationallicence Lamm Wolfgang Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut Eder Sandra Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut Bojic Marija Department of Medicine I, Bone Marrow Transplant Unit, Medical University of Vienna, Vienna, Austria aut Zielinski Christoph Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut Drach Johannes Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut Wiener klinische Wochenschrift Springer Vienna 127/3-4(2015-02-01), 92-97 0043-5325 127:3-4<92 2015 127 508 https://doi.org/10.1007/s00508-014-0605-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-014-0605-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lamm Wolfgang Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Eder Sandra Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Bojic Marija Department of Medicine I, Bone Marrow Transplant Unit, Medical University of Vienna, Vienna, Austria aut NATIONALLICENCE 700 1- Zielinski Christoph Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Drach Johannes Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/3-4(2015-02-01), 92-97 0043-5325 127:3-4<92 2015 127 508